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Green chemistryAbstract The current research and development scenario in medicinal chemistry demands small
molecules synthesized in a simple, fast and effective way with enhanced activity and fewer side
effects than the existing ones. Therefore, one-pot, microwave assisted green and efﬁcient synthesis
of a series of derivatives belonging to 2-phenyl 1,3-benzodioxole (1a–14a) and 2-phenyl 1,3-benzo-
dioxole-4-ol (1b–14b) class were carried out and subsequently investigated for their anticancer, anti-
bacterial and DNA binding potential. Compound 3c proved to be the most active one among the
screened derivatives possessing anticancer and antibacterial potency greater than the standard ref-
erence compound (cisplatin and cinoxacin for anticancer and antibacterial activity, respectively).
The most active compound in terms of DNA binding capacity was found to be 5b. A rewarding
feature of the work is a facile, convenient, eco friendly one step synthesis of compounds demon-
strating attenuated activity against cancer and bacterial cell with an inherent potential of binding
S1876 S. Dutta Gupta et al.to DNA. Subsequently, a hit molecule for further anticancer, antibacterial (compound 3c) and
DNA binding studies (compound 5b) was also identiﬁed.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Figure 1 2-aminophenyl benzothiazole.1. Introduction
The design of small molecules for better treatment of diseases
has become an important therapeutic objective, given the
wide-ranging side effects of existing molecules and rapid resis-
tance developed to them (Leaf, 2004; Allerberger and
Mittermayer, 2008). The benzothiazole nucleus is found in
many such promising small molecule anticancer and antibac-
terial agents which were evaluated up to advanced preclinical
stage (Racane et al., 2013). Among the small molecules with
a benzothiazole nucleus, the study of 2-phenyl substituted
benzothiazole (Fig. 1) derivatives is of considerable current
interest owing to their diverse biophysical and biological
properties. They are reported to possess antitumor (Kadri
et al., 2008), antibacterial (Bandyopadhyay et al., 2011), anti-
fungal (Dutta Gupta et al., 2010), antiparasitic (Kuvaev et al.,
2005) and antioxidant activity (Sharma et al., 2013). Further
they have strong activity proﬁle as imaging agents for b-amy-
loid protein which aids in non-invasive diagnosis of Alzhei-
mer’s disease (Weekes and Westwell, 2009).
The benzodioxole ring which is an isostere of benzothiazole
nucleus is also studied as antitumor (Wei et al., 2012), antibacte-
rial (Leite et al., 2004), antifungal (Bakhite and Radwan 1999),
antiparasitic (Kamau et al., 2011), antimalarial (Nelson and
Hoosseintehrani 1982) and antioxidant agents (Zhao et al.,
1997). Additionally some benzodioxole derivatives are also used
as pesticides or pesticide intermediates and herbicides (Ugolini
et al., 2005). The 1,3-benzodioxole system is also an integral part
of many natural products like sesamol (Shenoy et al., 2011) and
piperine (Srinivasan 2007). The extensive review of the literature
revealed that the 2-phenyl substituted benzodioxole ring system is
yet to be explored for various biological activities.
Discovery and development of a new drug molecule is a
lengthy and costly affair which may lead to stiﬂing of innova-
tion (DiMasi et al., 2003). Moreover, environment contamina-
tion involved in the discovery process of new chemical entities
is a global concern. Therefore, current medicinal chemistry
research strives for rapid synthesis of small molecules with
increased efﬁcacy and lesser side effects than the existing ones
in a simple, effective and environment friendly fashion.
From the above mentioned facts and based on the principle
of bioisosterism, fourteen compounds belonging to 2-phenyl
1,3-benzodioxole (Fig. 2a) and 2-phenyl 1,3-benzodioxol-4-ol
series (Fig. 2b) were synthesized using green chemistry approach
and subsequently evaluated for anticancer and antibacterial
activity. Subsequently, DNA binding studies were also carried
out to ascertain the mechanism of action of the compounds.
2. Experimental
2.1. Chemistry
The chemicals, reagents and solvents employed for synthesis
were procured from Hi-media Laboratories (Mumbai, India)and SD ﬁne-chem limited (Mumbai, India). The progress of
the reaction and purity were monitored by using TLC Silica
gel 60 F254 aluminium sheets (Merck F254, Darmstadt, Ger-
many) developed in mobile phase containing ethyl acetate
and petroleum ether (1:1). The melting point of the synthesized
compounds was determined by DRK Digital melting point
apparatus. IR spectra were recorded on Shimadzu IR-Afﬁnity
spectrometer using KBr pellets. The 1H spectra of the com-
pounds synthesized were acquired in deuterated DMSO on a
Bruker ARX 400 MHz (Bruker AG, Fallanden, Switzerland)
instrument. Tetramethylsilane was used as the internal stan-
dard and all chemical shift values were expressed in parts per
million (d, ppm). The mass spectra were obtained from 6120
Quadrupole LC/MS mass spectrometer using electron spray
ionization method. (Agilent Technologies, California, USA).
Compounds 1(a) to 14(a) were synthesized according to the
literature (Dutta Gupta et al., 2012).
2.1.1. General Procedure for the synthesis of 1(b) to 14(b)
Pyrogallol (1 mol equivalent) and benzoic acid derivatives
(1.05 mole equivalent) were heated in the microwave (Biotage
Initiator 2.5 at 350 W, 100 C for 30–120 s) in the presence of
polyphosphoric acid (0.1 mol equivalent, Tables 1 and 2). TLC
was observed to monitor the completion of the reaction by
using ethyl acetate: petroleum ether in the ratio of 1:1 as the
mobile phase. The reaction mass was neutralized with 10%
NaOH solution and then ﬁltered. The crude product was
recrystallized using 70% alcohol (Fig. 3).
2.2. In vitro cytotoxicity studies
The in-vitro cytotoxicity potential of the test compounds was
evaluated on A549 human lung carcinoma cells using MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bro-
mide] based cell proliferation assay (Van Meerloo et al.,
2011; Ferrari et al., 1990). The carcinoma cell lines were
obtained from National Centre for Cell Science (NCCS), Pune
(India) and cultivated in Dulbecco’s modiﬁed Eagle’s red med-
ium (DMEM) (Sigma Life Science, USA) containing 10% foe-
tal bovine serum (FBS). An equal number of cells were
incubated at 37 C with 5% CO2 in a 96 well micro plates.
Thereafter, the cells were treated with test compounds and
standard at concentration of 100 lg/ml. Control cells were
supplemented with 0.5% DMSO. After 72 h treatment, 5 ll
of MTT reagent along with 45 ml of phenol red and FBS free
DMEM was added to each well and plates were incubated at
37 C with 5% CO2 for 4 h. Subsequently, 50 ml of solubiliza-
tion buffer was added to each well to solubilize the coloured
Figure 2 Chemical structures of benzodioxole nucleus
synthesized.
Synthesis and evaluation of 2-phenyl 1,3-benzodioxole S1877formazan crystals produced by the reduction of MTT. After
24 hrs, the optical density was measured at 550 nm using a
spectrophotometer in a microplate reader (Bio-Rad, USA).
Cisplatin was used as standard reference compound.
2.3. DNA binding studies
The interaction of the compounds with calf thymus DNA was
studied in phosphate buffer of pH 7 using UV visible spectro-
photometer (Shimadzu, UV 1800) (Mansuri-Torshizi et al.,
2001). The hypochromic effect observed in the absorption
spectra of the molecules with increasing concentrations of
DNA (0–100 lM) is shown in Fig 4. The change in absorbance
was measured at 210–320 nm for synthetic compounds–DNA
complex. Scatchard equation was utilized to build the binding
isotherm. The half reciprocal UV plot obtained on the basis of
absorbance data for synthetic compounds-DNA complex is
depicted in Fig. 5. The linear plots obtained indicate the
involvement of one binding process with independent binding
sites on DNA. The parameters, kmax, hypochromicity, isobestic
point and binding constant were found from the absorption
spectra (Mansouri-Torshizi et al., 2008). The intrinsic binding
constant (Ki) for a given complex with DNA was obtainedTable 1 Details of 2-phenyl benzodioxole derivatives synthesized.
O
O
R
S. No. R1 R2 R3 R4 Reactant II
1a H H H H Benzoic acid
2a Cl H H H 4-Chloro benzoic acid
3a Me H H H 4-Methyl benzoic acid
4a Me OMe H H 3-methoxy-4-methyl benz
5a H H OH H 2-hydroxy benzoic acid
6a NH2 H H H 4-amino benzoic acid
7a H NH2 H H 3-amino benzoic acid
8a H H NH2 H 2-amino benzoic acid
9a H H N-CH3 H N-methyl-2-amino benzo
10a OH OCH3 H H Vanillic acid
11a Cl H Cl H 2,4–dichloro benzoic acid
12a OH OH H OH Gallic acid
13a H H OAc H Aspirin
14a H H COOH H Phthalic acidfrom a plot of D/Deapp versus D according to equation, D/
Deapp = D/De+ 1/De · K, where D= concentration of
DNA in base molarities, Deapp = |ea  ef| and De= |eb  ef|,
where ea and ef are respective extinction coefﬁcients of the
complex in the presence and absence of DNA. The apparent
extinction coefﬁcient ea is obtained by calculating Aobs/[Acri-
dones]. The data were ﬁtted to the equation with a slope equal
to 1/De and Y-intercept equal to 1/(De · K). Thereafter the
intrinsic binding constant (Ki) was determined from the slope
of Y-intercept.
2.4. Antibacterial studies
The microorganisms were procured from MTCC, Mumbai,
India. The in vitro antibacterial studies were carried out by
disc diffusion method in nutrient agar medium (Dutta Gupta
et al., 2010, Ednie et al., 2000) The screening of the compounds
was performed against Escherichia coli (MTCC 40, Gram neg-
ative), Pseudomonas aeruginosa (MTCC 424, Gram negative)
Bacillus subtilis (MTCC 441, Gram positive) and Staphylococ-
cus aureus (MTCC 3160, Gram positive) at concentration of
60, 80, 100, 120 and 140 lg/ml. Cinoxacin was used as stan-
dard reference drug. The required concentrations of the com-
pounds were prepared in sterile DMSO. The sterile growth
medium was poured into the petri plate and allowed to solid-
ify. Subsequently, the microbial suspension was swabbed on
agar bed using a sterile cotton swab. This was followed by
placing a sterile paper disc uniformly on the agar bed. The syn-
thesized compounds and standard drug contained in sterile
paper disc were allowed to diffuse for 10 min. Thereafter, the
petri plates were incubated for 24 h at 37 C. The zone of inhi-
bition was measured in mm to determine the antimicrobial
potency of the compounds.R1
R23
R4
Reaction
time (s)
Physical description Melting
point C
Rf
value
%
yield
30 White crystals 50–51 0.703 80.2
45 Light grey powder 102–105 0.393 75.8
60 Brownish powder 57–58 0.721 78.3
oic acid 45 Greyish powder 99–101. 0.750 82.5
90 White crystals 115–118 0.786 60.6
120 Brownish crystals 120–125 0.667 65.5
120 Creamish powder 130–134 0.634 68.9
105 Light brown crystals 188–190 0.626 62.8
ic acid 120 Light brown powder 174–175 0.661 68.4
45 White crystals 54–59 0.421 60.6
90 White powder 171–174 0.722 78.1.
120 Greyish crystals 178–180 0.328 61.3
105 White crystals 78–80 0.698 81.3
60 Greyish crystals 102–105 0.746 70.5
Table 2 Details of 2-phenyl benzodioxole-4-ol derivatives synthesized.
O
O
OH
R1
R2R3
R4
S. No. R1 R2 R3 R4 Reactant II Reaction
time (s)
Physical description Melting
point C
Rf
value
%
yield
1b H H H H Benzoic acid 30 White crystals 113–114 0.323 72.6
2b Cl H H H 4-Chloro benzoic acid 30 Pale white crystals 99–103 0.256 78.2
3b Me H H H 4-Methyl benzoic acid 90 Greyish powder 122–125 0.465 82.4
4b Me OMe H H 3-Methoxy-4-methyl benzoic acid 60 Dark brown powder 87–89 0.333 68.6
5b H H OH H 2-Hydroxy benzoic acid 60 White crystals 110–112 0.286 70.8
6b NH2 H H H 4-Amino benzoic acid 90 Light brown crystals 165–168 0.376 65.1
7b H NH2 H H 3-Amino benzoic acid 90 Creamish powder 154–156 0.365 60.6
8b H H NH2 H 2-Amino benzoic acid 120 Brownish crystals 180–182 0.343 61.4
9b H H N-CH3 H N-Methyl-2-amino benzoic acid 120 Brown powder 164–168 0.423 68.8
10b OH OCH3 H H Vanillic acid 30 Cream coloured crystals 72-73 0.289 62.6
11b Cl H Cl H 2,4-Dichloro benzoic acid 90 White powder 184–185 0.523 80.5
12b OH OH H OH Gallic acid 120 Cream coloured powder 180–183 0.275 60.2
13b H H OAc H Aspirin 90 White crystals 87–90 0.462 75.5
14b H H COOH H Phthalic acid 45 Greyish powder 112–113 0.491 76.8
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3.1. Chemistry
A series of 2 phenyl substituted 1,4-benzodioxole derivatives
were synthesized (Fig. 3) by green chemistry approach and
characterized as per literature (Dutta Gupta et al., 2012). In
a similar environment friendly fashion, one-pot synthesis of
a series of 2 phenyl substituted 1,4-benzdioxole-4-ol derivatives
were carried out by using polyphosphoric acid as solvent/cat-
alyst under microwave irradiation (Fig. 3). The physical prop-
erties of the synthesized compounds are summarized in Tables
1 and 2. The reaction is believed to proceed by the attack of the
hydroxyl group of benzoic acid by ‘H’ of polyphosphoric acid
to form the protonated benzoic acid which is attacked by cat-
echol/pyrogallol to form a tetrahedral intermediate that fur-
ther cyclizes to form the 1,3-benzodioxole ring. The
formation of the synthesized compounds was conﬁrmed by
IR, 1H NMR and mass spectral analysis. In the IR spectra
of compounds (1b–14b), the stretching bands due to one OH
group were detected in the range of 3498–3317 cm1. The com-
pounds 6b–9b showed a characteristic NH stretching band
between 3325 and 3381 cm1. In case of compound 2b and
11b, corresponding C–Cl stretching was observed at
732 cm1 and 761 cm1, respectively. In 1H NMR spectra of
the compounds (1b–14b), a single peak corresponding to the
CH proton of the dioxole ring system was observed between
7.0 and 7.5. The physical properties and percentage yield of
the synthesized compounds along with their IR, 1H NMR
and mass spectral data are given below.
3.1.1. 2-Phenylbenzo[d][1,3]dioxole (1a) (Cole et al., 1980)
It was obtained as a light grey solid, 80.2% yield, mp 50–51 C.3.1.2. 2-(4-Chlorophenyl)benzo[d][1,3]dioxole (2a)
It was obtained as a light grey solid, 75.8% yield, mp 102–105 C.
IR (KBr cm1): 1089 (CAO stretching), 3115 (aromatic CH
stretching), 758 (CACl stretching). 1H NMR (CDCl3, 400 MHz)
d: 6.8(d, 1H, ArH, J=6.4), 6.9 (d, 1H, ArH, J=6.5), 7.1 (d,
2H, ArH, J=7.1), 7.4 (s, 1H, dioxole CH), 7.6 (t, 2H, ArH),
8.1 (d, 2H, ArH, J=7.6). Mass (m/z): 199 (M+1).
3.1.3. 2-(4-Methylphenyl) benzo[d][1,3]dioxole (3a)
It was obtained as a brown solid, 78.3% yield, mp 57–58 C.
IR (KBr cm1): 1174 (CAO stretching), 3032 (aromatic CH
stretching). 1H NMR (CDCl3, 400 MHz) d: 6.8 (d, 2H, ArH,
J= 6.4), 6.9 (d, 2H, ArH, J= 6.5), 7.1 (t, 2H, ArH), 7.4 (s,
1H, dioxole CH), 8.0 (d, 2H, ArH, J= 7.6), 2.4 (s, 1H,
CH3). Mass (m/z): 232.6 (M+1).3.1.4. 2-(3-Methoxy-4-methylphenyl benzo[d][1,3]dioxole
(4a)
It was obtained as a grey solid, 82.5% yield, mp 99-101 C. IR
(KBr cm1): 1149 (CAO stretching), 3066 (aromatic CH
stretching). 1H NMR (CDCl3, 400 MHz) d: 6.9 (d, 1H, ArH,
J= 6.5), 7.0 (d, 1H, ArH, J= 6.5), 7.1 (s, 1H, ArH), 7.3 (s,
1H, dioxole CH), 7.5 (d, 1H, ArH), 7.6 (d, 1H, ArH,
J= 7.3), 7.7 (t, 2H, ArH, J= 7.1), 2.3 (s, 1H, CH3), 3.9 (s,
1H, OCH3). Mass (m/z): 242.2 (M+1).
3.1.5. 2-(2-Hydroxyphenyl benzo[d][1,3]dioxole (5a)
It was obtained as a white solid, 60.6% yield, mp 115–118 C.
IR (KBr cm1): 1155 (CAO stretching), 3007 (aromatic CH
stretching), 3238 (OH stretching). 1H NMR (CDCl3,
400 MHz) d: 6.9 (d, 3H, ArH, J= 6.4), 7.5 (d, 1H, ArH,
J= 7.5), 7.5 (t, 1H, ArH), 7.5 (s, 1H, dioxole CH), 7.7 (t,
Figure 3 Scheme of synthesis.
Figure 4 Effect of CT DNA on synthesized compound 3b.
Synthesis and evaluation of 2-phenyl 1,3-benzodioxole S18791H, ArH), 7.7 (t, 2H, ArH, J= 7.1), 5.2 (s, 1H, OH). Mass (m/
z): 214.0 (M+1).
3.1.6. 2-(4-Aminophenyl) benzo[d][1,3]dioxole (6a)
It was obtained as a brown solid, 65.5% yield, mp 120–125 C.
IR (KBr cm1): 1070 (CAO stretching), 3008 (aromatic CH
stretching), 3361 (NH stretching), 1332 (C„N stretching).
1H NMR (CDCl3, 400 MHz) d: 6.6 (d, 3H, ArH, J= 6.3),
7.2 (d, 1H, ArH, J= 7.0), 7.6 (t, 1H, ArH), 7.2 (s, 1H, dioxole
CH), 7.8 (t, 1H, ArH), 7.8 (d, 2H, ArH, J= 7.4), 4.0 (s, 1H,
NH stretching). Mass (m/z): 213.0 (M+1).
3.1.7. 2-(3-Aminophenyl) benzo[d][1,3]dioxole (7a)
It was obtained as a cream solid, 68.9% yield, mp 130–134 C.
IR (KBr cm1): 1153 (CAO stretching), 2985 (aromatic CHFigure 5 Half reciprocal UV plots for the binstretching), 3404 (NH stretching), 1274 (C„N stretching).
1H NMR (CDCl3, 400 MHz) d: 6.7 (d, 3H, ArH, J= 6.3),
7.0 (d, 2H, ArH, J= 6.5), 7.1 (t, 2H, ArH), 7.6 (s, 1H, dioxole
CH), 7.1 (d, 1H, ArH, J= 6.5), 4.9 (s, 1H, NH stretching).
Mass (m/z): 213.0 (M+1).
3.1.8. 2-(2-Aminophenyl) benzo[d][1,3]dioxole (8a)
It was obtained as a light brown solid, 62.8% yield, mp 188–
190 C. IR (KBr cm1): 1091 (CAO stretching), 2950 (aro-
matic CH stretching), 3300 (NH stretching), 1313 (C„N
stretching). 1H NMR (CDCl3, 400 MHz) d: 6.5(d, 2H, ArH,
J= 6.3), 6.7 (d, 2H, ArH, J= 6.5), 7.6 (t, 1H, ArH), 7.2 (s,
1H, dioxole CH), 7.6 (d, 1H, ArH, J= 7.2), 7.7(t,
1H, ArH), 4.9 (s, 1H, NH stretching). Mass (m/z): 213.0
(M+1).
3.1.9. 2-(N-methyl-2-aminophenyl) benzo[d][1,3]dioxole (9a)
It was obtained as a light brown solid, 68.4% yield, mp 174–
175 C. IR (KBr cm1): 1100 (CAO stretching), 2941 (aro-
matic CH stretching), 3387 (NH stretching), 1253 (C„N
stretching).. 1H NMR (CDCl3, 400 MHz) d: 6.5 (d, 2H,
ArH, J= 6.3), 6.6 (d, 2H, ArH, J= 6.3), 7.3 (t, 2H, ArH),
7.3 (s, 1H, dioxole CH), 7.7 (t, 1H, ArH), 2.8 (s, 1H, CH3),
4.8 (s, 1H, NH stretching). Mass (m/z): 227.1 (M+1).
3.1.10. 2-(3-Methoxy-4-hydroxyphenyl) benzo[d][1,3]dioxole
(10a)
It was obtained as a white solid, 60.6% yield, mp 54–59 C. IR
(KBr cm1): 1100 (CAOstretching), 3242 (aromaticCH stretch-
ing), 3435 (OH stretching). 1H NMR (CDCl3, 400 MHz) d: 6.2
(d, 2H, ArH, J= 6.0), 6.6 (s, 2H, ArH), 6.9 (t, 1H, ArH), 7.3
(s, 1H, dioxole CH), 7.3 (t, 1H, ArH), 3.8 (s, 3H, OCH3), 5.1
(s, 1H, OH stretching). Mass (m/z): 243.1 (M+1).ding of synthesized compound 3b to DNA.
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It was obtained as a white solid, 78.1% yield, mp 171–174 C.
IR (KBr cm1): 1116 (CAO stretching), 2993 (aromatic CH
stretching), 696 (CACl stretching). 1H NMR (CDCl3,
400 MHz) d: 7.2 (d, 2H, ArH, J= 6.8), 7.5 (s, 2H, ArH), 7.7
(d, 1H, ArH, J= 7.3), 7.6 (s, 1H, dioxole CH), 7.8 (t, 2H,
ArH). Mass (m/z): 267.1 (M+1).
3.1.12. 2-(3,4,5-Trihydroxyphenyl) benzo[d][1,3]dioxole
(12a)
It was obtained as a grey solid, 61.3% yield, mp 178–180 C.
IR (KBr cm1): 1072 (CAO stretching), 3051 (aromatic CH
stretching), 3460 (OH stretching). 1H NMR (CDCl3,
400 MHz) d: 6.7 (s, 2H, ArH), 6.7 (d, 1H, ArH, J= 6.3), 6.9
(d, 1H, ArH, J= 6.4), 7.4 (s, 1H, dioxole CH), 6.9 (t, 2H,
ArH), 5.1 (s, 1H,OH stretching). Mass (m/z): 246.9 (M+1).
3.1.13. 2-(2-Acetyloxyphenyl) benzo[d][1,3]dioxole (13a)
It was obtained as a white solid, 81.3% yield, mp 78–80 C. IR
(KBr cm1): 1105(CAO stretching), 3028(aromatic CH
stretching). 1H NMR (CDCl3, 400 MHz) d: 6.9 (d, 1H, ArH,
J= 6.4), 7.1 (d, 1H, ArH, J= 6.5), 7.3 (d, 1H, ArH,
J= 6.8), 7.4 (s, 1H, dioxole CH), 7.7 (t, 1H, ArH), 7.4 (d,
1H, ArH), 7.6 (d, 1H, ArH, J = 7.3) 7.7 (d, 1H, ArH,
J = 7.2), 7.9 (t, 1H, ArH), 2.2 (s, 1H, OCH3). Mass (m/z):
256.1 (M+1).
3.1.14. 2-(2-Carboxyphenyl) benzo[d][1,3]dioxole (14a)
It was obtained as a grey solid, 70.5% yield, mp 102–105 C.
IR (KBr cm1): 1111 (CAO stretching), 2980 (aromatic CH
stretching), 3429 (OH stretching). 1H NMR (CDCl3,
400 MHz) d: 7.1 (d, 1H, ArH, J= 6.5), 7.5 (d, 3H, ArH,
J= 7.2), 7.5 (s, 1H, dioxole CH), 7.6 (d, 2H, ArH, J= 7.3),
7.6 (t, 2H, ArH), 13 (s, 1H, COOH). Mass (m/z): 242.2 (M+1).
3.1.15. 2-Phenylbenzo[d][1,3]dioxol-4-ol (1b)
It was obtained as a white solid, 72.6% yield, mp 113–114 C.
IR (KBr cm1): 1141 (CAO stretching), 3182 (aromatic CH
stretching), 3498 (OH stretching). 1H NMR (CDCl3,
400 MHz) d: 7.4 (d, 2H, ArH J= 7.3), 7.6 (d, 2H, ArH
J= 7.4), 7.3 (s, 1H, dioxole CH), 8.1(t, 4H, ArH), 5.2 (s,
1H, OH). Mass (m/z): 213.9 (M1).
3.1.16. 2-(4-Chlorophenyl) benzo[d][1,3]dioxol-4-ol (2b)
It was obtained as a pale white solid, 78.2% yield, mp 99–
103 C. IR (KBr cm1): 1107 (CAO stretching), 3050 (aro-
matic CH stretching), 732 (CACl stretching). 3412 (OH
stretching). 1H NMR (CDCl3, 400 MHz) d: 6.4 (d, 2H, ArH,
J= 6.3), 6.6 (d, 1H, ArH, J= 6.4), 6.8(d, 1H, ArH), 7.3 (s,
1H, dioxole CH), 7.4 (d, 1H, ArH, J= 7.2), 7.9 (d, 1H,
ArH, J= 7.4), 7.9 (t, 1H, ArH), 5.2 (s, 1H, OH). Mass (m/
z): 248.7(M+1).
3.1.17. 2-(4-Methylphenyl) benzo[d][1,3]dioxol-4-ol (3b)
It was obtained as a grey solid, 82.4% yield, mp 122–125 C.
IR (KBr cm1): 1107 (CAO stretching), 3050 (aromatic CH
stretching), 3414(OH stretching). 1H NMR (CDCl3,
400 MHz) d: 6.2 (d, 2H, ArH, J= 6.1), 6.4 (d, 1H, ArH,
J= 6.2), 6.8 (d, 1H, ArH, J= 6.7), 7.3 (s, 1H, dioxole CH),7.4 (d, 1H, ArH, J= 7.3), 7.8 (d, 1H, ArH, J= 7.4), 7.8 (t,
1H, ArH), 2.3(s, 3H, CH3). Mass (m/z): 22.1 (M+1).3.1.18. 2-(3-Methoxy-4-methyl phenyl) benzo[d][1,3]dioxol-4-
ol (4b)
It was obtained as a dark brown solid, 68.6% yield, mp 87–
89 C. IR (KBr cm1): 1103 (CAO stretching), 2937(aromatic
CH stretching), 3417 (OH stretching). 1H NMR (CDCl3,
400 MHz) d: 6.6 (d, 2H, ArH, J= 6.3), 7.2 (s, 1H, dioxole
CH), 7.5(s, 1H, ArH), 7.5 (d, 2H, ArH, J= 7.3), 7.6 (d, 1H,
ArH, J= 7.3), 7.6(t, 1H, ArH), 2.3 (s, 3H, –OCH3), 2.3 (s,
3H, CH3). Mass (m/z): 258.8 (M+1).3.1.19. 2-(2-Hydroxyphenyl) benzo[d][1,3]dioxol-4-ol (5b)
It was obtained as a white solid, 70.8% yield, mp 110–112 C.
IR (KBr cm1): 1128 (CAO stretching), 2974 (aromatic CH
stretching), 3381 (OH stretching). 1H NMR (CDCl3,
400 MHz) d: 6.9 (d, 3H, ArH, J= 6.5), 7.3(s, 1H, dioxole
CH), 7.5 (d, 1H, ArH, J= 7.3), 7.5 (t, 1H, ArH), 7.7 (d,
2H, ArH, J= 7.4), 5.0 (s, 2H, OH). Mass (m/z): 230.1 (M+1).
3.1.20. 2-(4-Aminophenyl) benzo[d][1,3]dioxol-4-ol (6b)
It was obtained as a light brown solid, 65.1% yield, mp 165–
168 C. IR (KBr cm1): 1128(CAO stretching), 3051(aromatic
CH stretching), 1325(C„N stretching), 3381 (NAH stretch-
ing), 3460 (OH stretching). 1H NMR (CDCl3, 400 MHz) d:
6.2 (d, 3H, ArH, J= 6.0), 6.5 (d, 1H, ArH, J= 6.3), 6.5 (t,
1H, ArH), 7.2 (s, 1H, dioxole CH), 7.6 (t, 2H, ArH), 4.2 (s,
1H, –NH), 5.0 (s, 1H, OH). Mass (m/z): 229.1 (M+1).
3.1.21. 2-(3-Aminophenyl) benzo[d][1,3]dioxol-4-ol (7b)
It was obtained as a cream solid, 60.6% yield, mp 154–156 C.
IR (KBr cm1): 1153 (CAO stretching), 2985 (aromatic CH
stretching), 1332 (C„N stretching), 3300 (NAH stretching),
3406(OH stretching). 1H NMR (CDCl3, 400 MHz) d: 6.2 (d,
1H, ArH, J= 6.0), 6.4 (d, 1H, ArH, J= 6.3), 6.7(d, 2H,
ArH, J= 6.3), 6.7 (t, 1H, ArH), 7.0 (t, 2H, ArH), 7.1 (s,
1H, dioxole CH), 4.0(s, 1H, –NH), 5.0 (s, 1H, OH). Mass
(m/z): 228.1 (M1).
3.1.22. 2-(2-Aminophenyl) benzo[d][1,3]dioxol-4-ol (8b)
It was obtained as a brown solid, 61.4% yield, mp 180–182 C.
IR (KBr cm1): 1249 (CAO stretching), 3028 (aromatic CH
stretching), 1319 (C„N stretching), 3373 (NAH stretching),
3473 (OH stretching). 1H NMR (CDCl3, 400 MHz) d: 6.4(d,
1H, ArH, J= 6.3), 6.6 (d, 1H, ArH, J= 6.4), 7.1 (s, 1H, diox-
ole CH), 7.3(d, 2H, ArH, J= 7.2), 7.6(t, 1H, ArH), 7.7 (t, 2H,
ArH), 5.6(s, 1H, OH), 4.0(s, 1H, -NH). Mass (m/z): 229.1
(M+1).
3.1.23. 2-(N-methyl-2-aminophenyl) benzo[d][1,3]dioxol-4-ol
(9b)
It was obtained as a brown solid, 68.8% yield, mp 164–168 C.
IR (KBr cm1): 1095 (CAO stretching), 3050 (aromatic CH
stretching), 1280 (C„N stretching), 3325 (NAH stretching),
3450 (OH stretching). 1H NMR (CDCl3, 400 MHz) d: 6.5(d,
1H, ArH, J= 6.3), 6.6 (d, 1H, ArH, J= 6.4),7.0 (d, 1H,
ArH, J= 6.6), 7.3(d, 1H, ArH, J= 7.1), 7.3(t, 1H, ArH),
Synthesis and evaluation of 2-phenyl 1,3-benzodioxole S18817.4 (s, 1H, dioxole CH), 7.7 (t, 2H, ArH), 5.6 (s, 1H, OH), 4.8
(s, 1H, –NH), 2.8(s, 3H, CH3). Mass (m/z): 243.1 (M+1).
3.1.24. 2-(3-Methoxy-4-hydroxyphenyl) benzo[d][1,3]dioxol-
4-ol (10b)
It was obtained as a cream coloured solid, 62.6% yield, mp 72–
73 C. IR (KBr cm1): 1100 (CAO stretching), 3174 (aromatic
CH stretching), 3431 (OH stretching). 1H NMR (CDCl3,
400 MHz) d: 6.5 (d, 2H, ArH, J= 6.3), 6.9 (d, 1H, ArH,
J= 6.4), 7.3 (s, 1H, dioxole CH), 7.7 (s, 1H, ArH), 7.8 (t,
1H, ArH), 5.2 (s, 1H, OH), 3.8 (s, 3H, OCH3). Mass (m/z):
260.0 (M+1).
3.1.25. 2-(2,4-Dichlorophenyl) benzo[d][1,3]dioxol-4-ol (11b)
It was obtained as a white solid, 80.5% yield, mp 184–185 C.
IR (KBr cm1): 1091 (CAO stretching), 2981 (aromatic CH
stretching), 761 (CACl stretching). 3431 (OH stretching). 1H
NMR (CDCl3, 400 MHz) d: 6.2 (d, 2H, ArH, J= 6.1),
6.4(d, 1H, ArH, J= 6.2), 7.5 (s, 1H, dioxole CH), 7.7 (d,
1H, ArH, J= 6.3), 7.8 (s, 1H, ArH), 7.9 (t, 1H, ArH), 5.2(s,
1H, OH). Mass (m/z): 283.0 (M+1).
3.1.26. 2-(3,4,5-Trihydroxyphenyl) benzo[d][1,3]dioxol-4-ol
(12b)
It was obtained as a cream coloured solid, 60.2% yield, mp
180–183 C. IR (KBr cm1): 1095 (CAO stretching), 3050
(aromatic CH stretching), 3456 (OH stretching). 1H NMR
(CDCl3, 400 MHz) d: 6.2(d, 1H, ArH, J= 6.1), 6.4 (d, 1H,
ArH, J= 6.3), 6.7(s, 1H, ArH), 6.9 (s, 1H, ArH), 6.9 (t, 1H,
ArH), 6.9 (t, 1H, ArH), 7.0 (s, 1H, dioxole CH), 5.1 (s, 2H,
OH), 5.2 (s, 2H, OH). Mass (m/z): 262.1 (M+1).
3.1.27. 2-(2-Acetyloxyphenyl) benzo[d][1,3]dioxol-4-ol (13b)
It was obtained as a white solid, 75.5% yield, mp 87–90 C. IR
(KBr cm1): 1149(CAO stretching), 3018(aromatic CH
stretching), 3452(OH stretching). 1H NMR (CDCl3,
400 MHz) d: 6.8(d, 2H, ArH, J= 6.5), 7.1 (d, 1H, ArH,
J= 6.9), 7.4 (d, 1H, ArH, J= 7.1), 7.3(s, 1H, dioxole CH),
7.6 (d, 1H, ArH, J= 7.2), 7.7 (d, 1H, ArH, J= 7.3), 7.8(t,
1H, ArH), 5.0 (s, 1H, OH), 2.2 (s, 3H, OCH3). Mass (m/z):
272.2 (M+1).Table 3 In-vitro cytotoxicity studies of synthesized benzodi-
oxole derivatives against A549 human lung carcinoma cells.
Compound
code
% Proliferation
inhibition
Compound
code
% Proliferation
inhibition
1a 32.10 1b 12.30
2a 24.00 2b 34.80
3a 78.80 3b 31.40
4a 30.90 4b 10.64
5a 24.90 5b 19.80
6a 24.60 6b 36.00
7a 9.74 7b 20.30
8a 32.70 8b 40.30
9a 33.90 9b 52.90
10a 28.10 10b 43.10
11a 30.90 11b 36.10
12a 21.10 12b 28.30
13a 28.10 13b 38.50
14a 26.90 14b 32.70
Cisplatin 49.53.1.28. 2-(2-Carboxyphenyl) benzo[d][1,3]dioxol-4-ol (14b)
It was obtained as a grey solid, 76.8% yield, mp 112–113 C.
IR (KBr cm1): 1095 (CAO stretching), 3051 (aromatic CH
stretching), 3452(OH stretching). 1H NMR (CDCl3,
400 MHz) d: 7.2 (s, 1H, dioxole CH), 7.5 (d, 2H, ArH,
J= 7.1), 7.5 (d, 3H, ArH, J= 7.2), 7.6 (d, 1H, ArH,
J= 7.4), 7.6 (t, 1H, ArH), 5.1 (s, 1H, OH), 12.8 (s, 1H,
COOH). Mass (m/z): 258.8 (M+1).
3.2. In vitro cytotoxicity studies
All the compounds exhibited considerable amount of antican-
cer activity against A 549 human lung carcinoma cells in
terms of percentage cell proliferation inhibition (% CPI) at
a concentration of 100 lgm/ml. Compound 3a (%
CPI = 78.80) and 9b (% CPI = 52.90) were found to be
more potent than the standard (% CPI = 49.50). It wasrevealed that mostly compounds belonging to benzodioxole-
4-ol category (2b, 6b–14b) showed better anticancer activity
than the compounds without a hydroxy group at fourth posi-
tion of the benzodioxole ring (2a, 6a–14a). However this phe-
nomenon was reversed for compounds with unsubstituted
phenyl ring (1a, 1b), methyl (3a, 3b) or hydroxy (4a, 5a, 4b,
5b) substituted phenyl ring. Subsequently it was observed
that among 2-phenyl benzodioxole derivatives, mono substi-
tution at para position of the phenyl ring with a methyl
group (3a) was the most potent. In case of 2-phenyl benzodi-
oxole-4-ol derivatives, mono substitution with a methyl
amino group at second position of the phenyl ring (9b) was
found to be the most active compound. The percentage cell
proliferation inhibition of the synthesized compounds is
depicted in Table 3.3.3. DNA binding studies
The ability of the synthesized compounds to bind with DNA
as determined by binding constant value was found to be mod-
erate to mild. This can be attributed to a different mechanism
of action via which the compounds exhibit their cytotoxic
effects. The 2-phenyl benzodioxole-4-ol derivatives (1b–14b)
were found to be more effective than the 2-phenyl benzodiox-
ole class of compounds (1a–14a). Compound with a hydroxyl
group at second position of the phenyl ring (5a and 5b) was
found to be the most active in their respective series. The bind-
ing constant (Ki), kmax, % hypochromicity and isobestic point
is highlighted in Table 4.
3.4. Antibacterial studies
Antibacterial studies on the compounds bearing 2-phenyl
benzodioxole ring system (1a–14a) revealed that compound
3a is more potent than the standard against all the strains
of bacteria (Table 5). Compound 4a exhibited better activity
than the standard in terms of inhibiting S. aureus. It was fur-
ther disclosed that the activity of the compounds either
Table 5 Antibacterial activity of the compounds.
Compound Code Zone of inhibition (mm) in 100 lg/ml Compound Code Zone of inhibition (mm) in 100lg/ml
Strain I Strain II Strain III Strain IV Strain I Strain II Strain III Strain IV
1a 28 16 24 20 1b 18 14 16 12
2a 20 14 18 12 2b 12 12 16 12
3a 32 18 30 24 3b 20 15 22 16
4a 22 17 18 21 4b 12 9 18 11
5a 25 15 22 19 5b 15 14 20 14
6a 26 16 24 20 6b 16 16 22 18
7a 22 16 20 18 7b 12 14 16 13
8a 20 14 15 16 8b 10 10 13 12
9a 20 14 14 16 9b 12 11 12 11
10a 16 15 14 15 10b 11 12 10 13
11a 18 14 15 15 11b 16 14 15 14
12a 18 15 16 16 12b 15 11 16 16
13a 24 16 20 22 13b 17 14 19 19
14a 18 13 13 15 14b 11 11 9 10
Cinoxacin 31 16 28 20
Note: Strain I: Bacillus subtilis MTCC 441; Strain II: Staphyllococcous aureus MTCC 3160.
Strain III: Escherichia coli MTCC 40; Strain IV: Pseudomonas aeruginosa MTCC 424.
Table 4 Binding constant and photometric properties of 2-phenyl 1,2-benzodioxole derivatives in complex with CT DNA.
Compound
Code
Binding
constant (Ki)
k max
(nm)
% Hypochromicity Isobestic
point
Compound
Code
Binding
constant (Ki)
k max
(nm)
% Hypochromicity Isobestic
point
1a 1.6100 255 53.2 210 1b 1.7215 275 76.9 225
2a 0.6739 270 50.6 Unclear 2b 0.7346 295 43.2 Unclear
3a 0.6763 255 42.0 220 3b 0.9081 267 39.0 210
4a 0.9134 260 40.3 220 4b 1.3237 270 48.5 210
5a 2.5118 289 60.7 Unclear 5b 5.8739 310 83.5 218
6a 1.1641 296 41.0 245 6b 0.4257 315 36.6 220
7a 0.0442 290 22.3 250 7b 0.5481 309 30.8 Unclear
8a 1.4361 260 44.8 Unclear 8b 1.6860 273 52.5 215
9a 1.6878 260 65.6 210 9b 0.3419 271 45.5 Unclear
10a 0.3444 258 76.2 205 10b 0.6581 270 82.0 230
11a 0.6978 261 47.3 215 11b 0.7346 275 43.2 Unclear
12a 1.5067 260 58.2 218 12b 2.6540 275 64.4 235
13a 0.6154 259 60.5 Unclear 13b 1.1289 269 50.2 210
14a 1.5186 255 55.8 209 14b 0.5602 268 72.6 Unclear
S1882 S. Dutta Gupta et al.remained same or decreased when the phenyl ring is substi-
tuted with any group other than methyl at para position.
Substitution at other position of the phenyl ring did not
result in any signiﬁcant increase in potency. The activity data
of compounds belonging to 2-phenyl benzodioxole-4-ol cate-
gory (1b–14b) showed that all have considerable antibacterial
activity but none are potent than the reference standard.
Subsequently, a closer look at the activity proﬁle of this
series of compounds demonstrated that there is no marked
improvement in antibacterial property of the compounds
with a substitution in the phenyl ring at any position as
compared to unsubstituted phenyl ring (1b). However, in this
series also, compound 3b (methyl group at para position of
the phenyl ring, i.e. analogue of 3a) was the exception which
exhibited enhanced activity among all the derivatives of the
series. The result of antibacterial studies of the synthesized
compounds against various strains of bacteria is depicted in
Table 5.4. Conclusion
The present study identiﬁed some 2-phenyl 1,3-benzodioxole
derivatives with signiﬁcant anticancer and antibacterial prop-
erty, which may be associated with their DNA binding capac-
ity. For 2-phenyl 1,3-benzodioxole series, it was concluded that
substitution of 4 position of the phenyl ring with an electron
donating group having a atom with no unshared pair of elec-
tron (CH3) markedly increases anticancer and antibacterial
potential. In case of 2-phenyl 1,3-benzodioxole-4-ol series, it
was revealed that there is a drastic increase in anticancer and
antibacterial property when the second position of the phenyl
ring was substituted with a mono substituted atom bearing a
lone pair of electron (NCH3). Subsequently, the research work
identiﬁes 2-(4-methyl phenyl) 1,3-benzodioxole (3a) as a hit
molecule for further improvement of anticancer and antibacte-
rial potency and 2-(2-hydroxy phenyl) 1,3-benzodioxole-4-ol
(5b) as a hit molecule for the future development of DNA
Synthesis and evaluation of 2-phenyl 1,3-benzodioxole S1883binding agents. This study also provides a protocol for simple,
rapid, eco-sustainable and effective synthesis of 2-phenyl 1,3-
benzodioxole derivatives which may be explored further for
better activity proﬁle against cancer and bacterial cells.Acknowledgements
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